3 unknown, 2 active not recruiting, 2 completed, 2 recruiting. 5 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Unknown 2, Active not recruiting 1, Not yet recruiting 1, Recruiting 1 |
| Phase 1 | 4 | Completed 2, Recruiting 1, Withdrawn 1 |
Follow Metastatic Cervical Carcinoma: new trials by email Literature Review of Metastatic Cervical Carcinoma trials Research Report on Metastatic Cervical Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 50 | 2026-12-01 | 2026-09-17 |
| STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma Aldesleukin, Biopsy, Biospecimen Collection - Locally Advanced Cervical Carcinoma, Locally Advanced Colorectal Carcinoma | Phase 1 | Withdrawn | City of Hope Medical Center | 2025-12-05 | 2025-12-24 | |
| Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform Biospecimen Collection, Tissue Collection - Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma | Recruiting | Mayo Clinic | 324 | 2024-04-24 | 2026-03-12 | |
| Dostarlimab and Cobolimab in Advanced Cervical Cancer Dostarlimab, Cobolimab - Cervical Cancer, Advanced Cervical Carcinoma | Phase 2 | Active not recruiting | Meghan Shea | 66 | 2024-03-11 | 2026-01-13 |
| Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 138 | 2022-03-31 | 2026-08-20 |
| Tislelizumab and Radiotherapy for Recurrent Cervical Cancer Tislelizumab plus radiotherapy - Recurrent Cervical Carcinoma, Metastatic Cervical Carcinoma | Phase 2 | Unknown | Lei Li | 58 | 2022-03-27 | 2022-04-11 |
| Donafenib for Recurrent Cervical Cancer Donafenib combined with paclitaxel and platinum ± PD-1 antibody - Targeted Therapy, Chemotherapy | Phase 2 | Unknown | Lei Li | 20 | 2022-03-27 | 2022-04-04 |
| PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer Radiotherapy for targeted lesions and PD-1 antibody - Immune Checkpoint Inhibitors, Anti-programmed Death-1 Antibody | Unknown | Lei Li | 20 | 2022-03-26 | 2022-04-11 | |
| Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer Biospecimen Collection - Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Active not recruiting | Mayo Clinic | 18 | 2020-11-17 | 2025-10-27 | |
| Paclitaxel Therapeutic Drug Monitoring in Cancer Patients Blood draws, QLQ-CIPN20 Survey, PR-CTCAE Survey - Solid Tumor, Adult, Metastatic Nonsmall Cell Lung Cancer | Suspended | Wake Forest University Health Sciences | 55 | 2019-11-11 | 2026-08-13 | |
| Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis Ipilimumab, Laboratory Biomarker Analysis, Nivolumab - Malignant Peritoneal Neoplasm, Malignant Retroperitoneal Neoplasm | Phase 1 | Completed | M.D. Anderson Cancer Center | 26 | 2018-09-21 | 2025-05-22 |
| Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers Durvalumab, Laboratory Biomarker Analysis, Stereotactic Radiosurgery - Advanced Cervical Adenocarcinoma, Advanced Vaginal Carcinoma | Phase 1 | Completed | M.D. Anderson Cancer Center | 20 | 2018-07-18 | 2023-09-13 |
Uterine Cervical Neoplasms (12) · Carcinoma, Non-Small-Cell Lung (4) · Carcinoma, Renal Cell (4) · Neoplasm Metastasis (4) · Colorectal Neoplasms (3) · Endometrial Neoplasms (3) · Lung Neoplasms (3) · Melanoma (3) · Carcinoma, Hepatocellular (2) · Carcinoma, Merkel Cell (2) · Carcinoma, Transitional Cell (2) · Carcinosarcoma (2) · Clear-cell metastatic renal cell carcinoma (2) · Ovarian Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2)
Female Urogenital Diseases (12) · Female Urogenital Diseases and Pregnancy Complications (12) · Genital Diseases (12) · Genital Diseases, Female (12) · Genital Neoplasms, Female (12) · Neoplasms (12) · Neoplasms by Site (12) · Urogenital Diseases (12) · Urogenital Neoplasms (12) · Uterine Cervical Diseases (12) · Uterine Diseases (12) · Uterine Neoplasms (11) · Digestive System Diseases (5) · Digestive System Neoplasms (5) · Skin Diseases (5)
Specimen Handling (4) · Magnetic Resonance Spectroscopy (3) · Biopsy (2) · Blood Specimen Collection (2) · Cyclophosphamide (2) · Immunoglobulin G (2) · Nivolumab (2) · Radiotherapy (2) · CTLA-4 Antigen (1) · Colony-Stimulating Factors (1) · Disulfides (1) · Ipilimumab (1) · Paclitaxel (1) · Pharmacogenomic Variants (1) · Radiosurgery (1)
Lei Li (3) · Mayo Clinic (3) · M.D. Anderson Cancer Center (2) · City of Hope Medical Center (1) · Fred Hutchinson Cancer Center (1) · Meghan Shea (1) · Wake Forest University Health Sciences (1)
United States (7) · China (3) · Uganda (1)
Lei Li, M.D. (3) · Allison E. Garda, MD (1) · Amir A Jazaeri (1) · Dev Mukhopadhyay, PhD (1) · Lilie L Lin (1) · Meghan Shea, MD (1) · Roy Strowd, MD (1) · Shailender Bhatia, MD (1) · Vincent Chung (1) · Yanyan Lou, MD, PhD (1)
PMID 38471508, PMID 40791544, PMID 41484629
P30CA012197 (1), P30CA033572 (1)